ERBB2 and breast cancer: The predictive power of this platform is investigated by assessing BC-PDE responses to a typical standard-of-care regime of 5-fluorouracil, epirubicin, and docetaxel and to the HER2 antibody-directed therapy trastuzumab, with our data showing that BC-PDE responses are consistently reflective of clinical parameters.